Analyst Marc Goodman of Leerink Partners maintained a Buy rating on Axsome Therapeutics, with a price target of $150.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Marc Goodman has given his Buy rating due to a combination of factors that highlight Axsome Therapeutics’ strong performance and future potential. The company reported impressive sales figures for its key products, Auvelity and Sunosi, which exceeded expectations. Auvelity, in particular, is showing a promising growth trajectory, supported by an expanded sales force and anticipated further acceleration in the latter half of 2025. Additionally, the potential approval for an Alzheimer’s disease agitation indication could significantly boost the product’s market presence in 2026.
Goodman also notes the successful launch of Symbravo, which, despite conservative sales expectations, has begun to establish its market presence. The company’s financial position appears robust, with a substantial cash reserve expected to support operations until they achieve cash flow positivity. These positive developments have led to an upward revision of sales forecasts and earnings per share estimates, reinforcing the Buy recommendation for Axsome Therapeutics.
According to TipRanks, Goodman is a 4-star analyst with an average return of 5.7% and a 48.28% success rate. Goodman covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Evolus, and Axsome Therapeutics.
In another report released today, UBS also maintained a Buy rating on the stock with a $144.00 price target.